

# Association of Bleeding and Thrombosis With Outcome in Extracorporeal Life Support\*

Heidi J. Dalton, MD<sup>1</sup>; Pamela Garcia-Filion, PhD, MPH<sup>2</sup>; Richard Holubkov, PhD<sup>3</sup>; Frank W. Moler, MD<sup>4</sup>; Thomas Shanley, MD<sup>4</sup>; Sabrina Heidemann, MD<sup>5</sup>; Kathleen Meert, MD<sup>5</sup>; Robert A. Berg, MD<sup>6</sup>; John Berger, MD<sup>7</sup>; Joseph Carcillo, MD<sup>8</sup>; Christopher Newth, MD<sup>9</sup>; Richard Harrison, MD<sup>10</sup>; Allan Doctor, MD<sup>11</sup>; Peter Rycus<sup>12</sup>; J. Michael Dean, MD<sup>3</sup>; Tammara Jenkins, MSN, RN<sup>13</sup>; Carol Nicholson, MD<sup>13</sup>; for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network

## \*See also p. 193.

<sup>1</sup>Department of Child Health, Critical Care Medicine, Phoenix Children's Hospital and University of Arizona College of Medicine-Phoenix, Phoenix, AZ.

<sup>2</sup>Critical Care Medicine, Phoenix Children's Hospital, Phoenix, AZ.

<sup>3</sup>Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT.

<sup>4</sup>Department of Pediatrics, University of Michigan, Ann Arbor, MI.

<sup>5</sup>Department of Pediatrics, Children's Hospital of Michigan, Detroit, MI.

<sup>6</sup>Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.

<sup>7</sup>Department of Pediatrics, Children's National Medical Center, Washington, DC.

<sup>8</sup>Department of Critical Care and Anesthesia, Children's Hospital of Pittsburgh, Pittsburgh, PA.

<sup>9</sup>Department of Anesthesiology and Critical Care Medicine, Children's Hospital Los Angeles, Los Angeles, CA.

<sup>10</sup>Department of Pediatrics, University of California at Los Angeles, Los Angeles, CA.

<sup>11</sup>Departments of Pediatrics and Biochemistry, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO.

<sup>12</sup>The Extracorporeal Life Support Organization, Ann Arbor, MI.

<sup>13</sup>Pediatric Trauma and Critical Illness Branch, Eunice Kennedy Shriver National Institutes of Child Health and Human Development, The National Institutes of Health, Bethesda, MD.

Supported, in part, by the following cooperative agreements from the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services: U10HD050096, U10HD049981, U10HD049983, U10HD050012, U10HD063108, U10HD063106, U10HD063114, and U01HD049934.

Dr. Dalton received royalties from the *Rogers Textbook of Critical Care Medicine* and received support for article research from the National Institutes of Health (NIH). Her institution received grant support: this work was supported, in part, by the following cooperative agreements from the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, NIH, Department of Health and Human Services: U10HD050096, U10HD049981, U10HD049983, U10HD050012, U10HD063108, U10HD063106, U10HD063114, and U01HD049934 (centers who participated in this project were those in the Collaborative Pediatric Critical Care Research Network); consulted for rEVO Biologics; and lectured for rEVO Biologics. Dr. Garcia-Filion's institution received grant support from the NICHD (paid under the grant for the Collaborative

Copyright © 2015 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies

DOI: 10.1097/PCC.0000000000000317

Pediatric Critical Care Research Network [CPCCRN]). Dr. Holubkov served as a board member for Pfizer Inc. (Data Safety Monitoring Board), consulted for St. Jude Medical Inc. (biostatistical consultation), and received support for article research from the NIH. Dr. Holubkov and his institution received grant support from the NIH CPCCRN (coordinating center funding for CPCCRN). Dr. Moler received support for article research from the NIH. Dr. Shanley consulted for Case Western Res University (EAB Member), received royalties from Springer (Springer for text book editing), received support for travel from SPR (secretary-treasurer for SPR), and received support for article research from the NIH. His institution received grant support from the NIH (CPCCRN funding and NIH grants) and received support for travel from the NIH (CPCCRN Funding). Dr. Heidemann received support for article research from the NIH. Her institution received grant support and support for travel. Dr. Meert received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Berg received support for article research from the NIH. His institution received grant support (This study was funded by the NICHD CPCCRN grant. Dr. Berg is a PI on the grant) and received support for travel (travel to CPCCRN meetings to discuss this study funded by NICHD CPCCRN grant). Dr. Berger received support for article research from NIH. His institution received grant support from the NICHD/NIH. Dr. Carcillo received support for article research from the NIH. His institution received grant support and support for travel. Dr. Newth received support for article research from the NIH. His institution received grant support from the NICHD and the Collaborative Pediatric Critical Care Research Network. Dr. Harrison received support for article research from the NIH. His institution received grant support and support for travel from the NIH and CPCCRN. Dr. Dean received support for article research from the NIH. His institution received grant support from the NIH. Dr. Jenkins received support for article research from the NIH and disclosed government work. Dr. Nicholson received support for article search from the NIH and disclosed government work. Dr. Rycus disclosed that he does not have any potential conflicts of interest.

For information regarding this article, E-mail: heidi.dalton26@gmail.com

**Objective:** Changes in technology and increased reports of successful extracorporeal life support use in patient populations, such as influenza, cardiac arrest, and adults, are leading to expansion of extracorporeal life support. Major limitations to extracorporeal life support expansion remain bleeding and thrombosis. These complications are the most frequent causes of death and morbidity. As a pilot project to provide baseline data for a detailed evaluation of bleeding and thrombosis in the current era, extracorporeal life support patients were analyzed from eight centers in the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network.

**Study Design:** Retrospective analysis of patients (< 19 yr) reported to the Extracorporeal Life Support Organization registry from eight Collaborative Pediatric Critical Care Research Network centers between 2005 and 2011.

**Setting:** Tertiary children's hospitals within the Collaborative Pediatric Critical Care Research Network.

**Subjects:** The study cohort consisted of 2,036 patients (13% with congenital diaphragmatic hernia).

**Interventions:** None.

**Main Results:** In the cohort of patients without congenital diaphragmatic hernia ( $n = 1,773$ ), bleeding occurred in 38% of patients, whereas thrombosis was noted in 31%. Bleeding and thrombosis were associated with a decreased survival by 40% (relative risk, 0.59; 95% CI, 0.53–0.66) and 33% (odds ratio, 0.67; 95% CI, 0.60–0.74). Longer duration of extracorporeal life support and use of venoarterial cannulation were also associated with increased risk of bleeding and/or thrombotic complications and lower survival. The most common bleeding events included surgical site bleeding (17%;  $n = 306$ ), cannulation site bleeding (14%;  $n = 256$ ), and intracranial hemorrhage (11%;  $n = 192$ ). Common thrombotic events were clots in the circuit (15%;  $n = 274$ ) and the oxygenator (12%;  $n = 212$ ) and hemolysis (plasma-free hemoglobin > 50 mg/dL) (10%;  $n = 177$ ). Among patients with congenital diaphragmatic hernia, bleeding and thrombosis occurred in, respectively, 45% ( $n = 118$ ) and 60% ( $n = 159$ ). Bleeding events were associated with reduced survival (relative risk, 0.62; 95% CI, 0.46–0.86) although thrombotic events were not (relative risk, 0.92; 95% CI, 0.67–1.26).

**Conclusions:** Bleeding and thrombosis remain common complications in patients undergoing extracorporeal life support. Further research to reduce or eliminate bleeding and thrombosis is indicated to help improve patient outcome. (*Pediatr Crit Care Med* 2015; 16:167–174)

**Key Words:** bleeding; cardiopulmonary bypass; complications; extracorporeal life support; extracorporeal membrane oxygenation; thrombosis

Extracorporeal life support (ECLS) is a modified form of cardiopulmonary bypass that provides temporary support to neonates, children, and adults with refractory organ failure (1–3). Over 58,000 patients have been reported to have received ECLS, according to the Extracorporeal Life Support Organization (ELSO) International Registry (4). Changes in technology and the successful use of ECLS in patient populations such as influenza, cardiac arrest, and adults are driving a higher utilization of ECLS in recent years (4–14).

Use of ECLS is accompanied by a significant risk for complications that contribute to risk of death and disability (1–3). Exposure to the extracorporeal circuit induces a prothrombotic state, indicating need for vigilant monitoring of anticoagulation to prevent clotting in the extracorporeal circuit. Traditionally, clinicians rely on unfractionated heparin for anticoagulation. Despite advances in monitoring techniques and treatment of abnormalities in the coagulation cascade during ECLS, bleeding and thrombosis remain predominate complications (15–17). Intracranial

hemorrhage and ischemic stroke are the most severe such complications, often resulting in death or significant disability.

The ELSO established a voluntary registry on the clinical use of ECLS (predominantly extracorporeal membrane oxygenation, also known as ECMO) (<http://www.elseo.org>). ELSO implemented the registry to monitor the use of ECLS technology for identification of opportunities to improve practice guidelines and outcomes. Registry data include pre-ECLS clinical characteristics, primary diagnosis, reason for ECLS, ECLS variables, ELSO diagnostic category, complications, and outcome. Although the ELSO database is of great use in descriptions and outcomes of ECLS support, information collected is limited in scope.

This study leveraged the ELSO registry data to evaluate ECLS-related bleeding and thrombotic complications within the Collaborative Pediatric Critical Care Research Network (CPCCRN) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The CPCCRN, a network of eight medical centers with a focus on pediatric critical care research, are academic sites with dedicated ICU research personnel, pediatric training programs, have more than 20 ICU beds, and average yearly admissions to the ICU of more than 2,000. All are experienced ECLS centers, supporting more than 20 ECLS-treated patients per year, and each center within CPCCRN is a designated ELSO center of excellence (details at <http://www.ELSO.org>). Using the ECLS expertise within CPCCRN and the data available within the ELSO registry, we analyzed the bleeding and thrombosis complication rate and the association of such complications with survival. Findings from this study provided baseline data to inform the design of a prospective, observational cohort study of factors associated with bleeding, thrombosis, outcome, anticoagulation regimens, and compliance with center-specific protocols at CPCCRN sites.

## METHODS

We analyzed ELSO registry data for pediatric patients (< 19 yr) who underwent ECLS at any of the eight current CPCCRN centers during a 7-year period (2005–2011). The study outcomes were the prevalence of reported bleeding and thrombotic complications (definition described below) and survival to hospital discharge.

Approval to include deidentified data from each center was obtained, and the study was considered exempt by the Institutional Review Board at Phoenix Children's Hospital.

## Complications

For this study, bleeding complications extracted from the ELSO registry were identified as bleeding at the cannula site or any surgical site, intracranial hemorrhage, gastrointestinal hemorrhage, or pulmonary hemorrhage. A list of complications tracked within the ELSO database is shown in **Table 1** with those of interest highlighted in bold type. A thrombotic complication was reported clotting of the circuit (bridge, hemofilter, oxygenator, bladder, or "other"), presence of disseminated intravascular coagulation (DIC), and infarction in

**TABLE 1. List of Extracorporeal Life Support Organization Mechanical and Patient-Related Complications<sup>a</sup>**

| Patient-related                                    | Mechanical                |
|--|---------------------------|
| <b>Thrombotic</b>                                  | <b>Clots: oxygenator</b>  |
| <b>Intracranial infarction (US or CT)</b>          | <b>Clots: bridge</b>      |
| <b>Hemorrhagic</b>                                 | <b>Clots: bladder</b>     |
| <b>Intracranial hemorrhage (US or CT)</b>          | <b>Clots: hemofilter</b>  |
| <b>Gastrointestinal hemorrhage</b>                 | <b>Clots: other</b>       |
| <b>Cannulation site bleeding</b>                   | Oxygenator failure        |
| <b>Surgical site bleeding</b>                      | Raceway rupture           |
| <b>Hemolysis (plasma hemoglobin &gt; 50 mg/dL)</b> | Other tubing rupture      |
| <b>Disseminated intravascular coagulation</b>      | Pump malfunction          |
| <b>Pulmonary hemorrhage</b>                        | Heat exchange malfunction |
| Cardiopulmonary complications                      | Air in circuit            |
| Inotropes on extracorporeal life support           | Cracks: Connectors        |
| Myocardial stun by echocardiography                | Cannula problems          |
| Cardiopulmonary resuscitation required             |                           |
| Cardiac arrhythmia                                 |                           |
| Hypertension requiring vasodilator                 |                           |
| Patent ductus arteriosus                           |                           |
| Tamponade: blood, serous, air                      |                           |
| Pulmonary pneumothorax (requiring treatment)       |                           |
| Neurologic complications                           |                           |
| Clinical brain death                               |                           |
| Clinical seizures                                  |                           |
| Electroencephalography-detected seizures           |                           |
| Infection  |                           |
| Renal related                                      |                           |
| Continuous arteriovenous dialysis required         |                           |
| Creatinine (1.5–3.0)                               |                           |
| Creatinine (> 3.0)                                 |                           |
| Dialysis required                                  |                           |
| Hemofiltration required                            |                           |

(Continued)

**TABLE 1. (Continued) List of Extracorporeal Life Support Organization Mechanical and Patient-Related Complications<sup>a</sup>**

| Patient-related    | Mechanical |
|--------------------|------------|
| Metabolic related  |            |
| Glucose < 40       |            |
| Glucose > 240      |            |
| Hyperbilirubinemia |            |
| pH < 7.2           |            |
| pH > 7.6           |            |

US = ultrasound, CT = computed tomography.

<sup>a</sup> Adapted from International Extracorporeal Life Support Organization registry, with permissions. Complications of interest are noted in boldface font.

the CNS. Hemolysis, defined as a plasma hemoglobin more than 50 mg/dL, was also classified as a thrombotic complication. Of note, specific volume, severity scores, or timing within the ECLS run for observed complications do not exist within the ELSO Registry.

**Analysis**

Data were analyzed using Stata SE 11.0 (College Station, TX). Descriptive data are presented as median with interquartile range (IQR). The study cohort was stratified based on age: neonatal (< 31 d) and pediatric (age 31 d to 18 yr).

The study outcomes (bleeding and thrombotic complications, survival to discharge) were stratified into four groups based on the indication for ECLS support. These groups were ECMO for respiratory failure, cardiac failure, ECMO applied during cardiopulmonary resuscitation (ECPR), and congenital diaphragmatic hernia (CDH). The mode of ECLS was based on initial method of cannulation as either venoarterial or venovenous. Duration of ECMO and mode of cannulation were compared with complication events and survival outcome using regression to estimate the associated risk (relative risk [RR]; 95% CI). The distribution of ECLS-associated complications and survival were examined and compared between years of ECLS and age groups (neonatal vs pediatric) using chi-square analysis.

Regression models, with covariates when necessary, were constructed to estimate the RR for the association of complications with survival to hospital discharge. Adjustment for venoarterial was restricted to those in the respiratory setting as venoarterial was used almost exclusively for other indications. Inclusion of potentially significant confounders (e.g., organ dysfunction and severity of illness) was limited by data availability within the ELSO registry. RR ratios are presented with 95% CI. For ordinal independent variables (e.g., year of ECLS and number of complications for individual patients), a linear test for trend was performed. The *p* values for trend tests (*p*<sub>trend</sub>) were derived by entering the ordinal variable as a continuous variable in the model (18). Stratum-specific estimates were obtained when statistical significance was reached. The

**TABLE 2. Characteristics of the Study Cohort (n = 2,036)**

| Variable                                     | Percent (%) <sup>a</sup> | n     |
|--|--------------------------|-------|
| Male (n = 2,011)                             | 56                       | 1,132 |
| Neonatal (non-CDH)                           | 56                       | 1,001 |
| Race/ethnicity (n = 1,993)                   |                          |       |
| Caucasian                                    | 48                       | 963   |
| Hispanic                                     | 19                       | 385   |
| African-American                             | 22                       | 447   |
| Asian-Pacific Islander                       | 3                        | 68    |
| Other  | 7                        | 130   |
| Conventional ventilator (non-CDH)            | 63                       | 772   |
| Indication for extracorporeal life support   |                          |       |
| Respiratory                                  | 39                       | 784   |
| Neonates                                     | 66                       | 520   |
| Pediatric                                    | 34                       | 264   |
| Cardiac                                      | 36                       | 727   |
| Neonates                                     | 51                       | 372   |
| Pediatric                                    | 49                       | 355   |
| Extracorporeal cardiopulmonary resuscitation | 13                       | 262   |
| Neonatal                                     | 42                       | 109   |
| Pediatric                                    | 58                       | 153   |
| CDH  | 13                       | 263   |

CDH = congenital diaphragmatic hernia.

<sup>a</sup>Percents were rounded to the nearest integer.

statistical significance was defined as an  $\alpha$  of 0.05, with two-sided alternative hypotheses.


## RESULTS

Over the study period, 2,036 patients were supported with ECLS at eight CPCCRN centers. Of these, 263 received support for CDH. Study cohort details are shown in **Table 2**.

### Outcome of Neonatal and Pediatric ECLS Patients (Non-CDH)

Among the non-CDH patients, overall survival to discharge was 56% ( $n = 1,001/1,773$ ), with pediatric survival of 53% and neonatal survival of 59%. The primary indication was respiratory failure in 784 patients (44%), cardiac failure in 727 (41%), and ECPR in 262 patients (15%). Venoarterial support was used in 64% of patients with respiratory failure ( $n = 461/722$ ) and almost exclusively in cardiac failure and ECPR (> 99% of patients).

An increase in survival was noted from 53% in 2005 to 57% in 2011 ( $p_{\text{trend}} = 0.003$ ). When a linear effect of year is fitted, annual survival rates for neonatal ( $p_{\text{trend}} = 0.034$ ) and pediatric ( $p_{\text{trend}} = 0.014$ ) patients also improved over time; however,



**Figure 1.** Annual survival and complication rates (excludes cases of congenital diaphragmatic hernia). CPCCRN = Collaborative Pediatric Critical Care Research Network.


an unexplained decrease in survival is noted among pediatric patients from 61% in 2010 to 49% in 2011. Survival did not vary between CPCCRN centers ( $p = 0.294$ ) among neonatal ( $p = 0.854$ ) or pediatric ( $p = 0.244$ ) patients.

### Factors Associated With Outcome in Non-CDH Patients

Median duration of ECLS was 131 hours (IQR, 73–216). For every 10 hours of ECMO, the risk of complications and death increased (RR, 1.005; 95% CI, 1.003–1.007; RR, 1.005; 95% CI, 1.003–1.007, respectively). Among patients supported for respiratory failure, venoarterial cannulation mode increased the risk of complications (RR, 1.15; 95% CI, 1.04–1.26) and death (RR, 1.86; 95% CI, 1.42–2.44).

Complication rates for neonatal and pediatric patients steadily declined over the study years ( $p_{\text{trend}} < 0.001$ ) (**Fig. 1**). Bleeding complications occurred in 33% of neonates and 45% of pediatric patients. Thrombotic complications (840 events) occurred in 29% of neonates and 33% of pediatric patients.

Bleeding and thrombosis were associated with decreased survival (RR, 0.59; 95% CI, 0.53–0.66) and 33% (RR, 0.67; 95% CI, 0.60–0.74), respectively. The most common bleeding events included surgical site bleeding (17%;  $n = 306$ ), cannulation site bleeding (14%;  $n = 256$ ), and intracranial hemorrhage (11%;  $n = 192$ ). Thrombotic events included clots in the circuit (15%;  $n = 274$ ), clots in the oxygenator (12%;  $n = 212$ ), hemolysis (free hemoglobin > 50 mg/dL) (10%;  $n = 177$ ), intracranial infarction (4%;  $n = 74$ ), and DIC (3%;  $n = 59$ ) (**Fig. 2**).



**Figure 2.** Prevalence of bleeding and thrombotic complications. CDH = congenital diaphragmatic hernia, DIC = disseminated intravascular coagulation, GI = gastrointestinal.

**Patients Requiring ECLS for Respiratory Failure**

Survival to discharge in patients supported for respiratory failure was 68% ( $n = 530/784$ ), with neonatal survival of 77% and 50% in pediatric patients. The annual survival rates trended upward; however, this was not statistically significant ( $p_{\text{trend}} = 0.053$ ). Increased survival was noted in pediatric respiratory patients ( $p_{\text{trend}} = 0.005$ ), but neonatal survival was unchanged over time ( $p_{\text{trend}} = 0.380$ ).

The prevalence of bleeding and thrombotic-related complications in neonatal and pediatric patients requiring respiratory support is presented in **Figure 2**. Among neonatal patients, bleeding occurred in 25% ( $n = 131$ ) and thrombosis in 27% ( $n = 141$ ). Bleeding events were associated with decreased survival ( $RR_{\text{adj}}$  0.68; 95% CI, 0.58–0.80) as were thrombotic events ( $RR_{\text{adj}}$  0.79; 95% CI, 0.69–0.92). Compared with neonatal patients, pediatric patients had a higher prevalence of bleeding (50%,  $n = 131$ ;  $p < 0.001$ ) and thrombotic (37%,  $n = 98$ ;  $p = 0.004$ ) complications. Bleeding complications in pediatric patients were associated with a decrease in survival likelihood ( $RR_{\text{adj}}$  0.67; 95% CI, 0.51–0.87).

An increased number of bleeding complications were associated with decreased likelihood of survival for both neonatal and pediatric patients ( $p_{\text{trend}} = 0.001$ ) (**Table 3**). The frequency of thrombotic-related complications was associated with reduced survival in neonatal patients ( $p_{\text{trend}} = 0.009$ ) but was not associated with survival for pediatric patients ( $p_{\text{trend}} = 0.274$ ).

**Patients Requiring ECLS for Cardiac Failure**

Survival in patients receiving ECLS for cardiac failure was 49% ( $n = 353/727$ ), increasing from 44% in 2005 to 52% in 2011

( $p_{\text{trend}} = 0.010$ ) (**Fig. 1**). Bleeding and thrombotic-related events were noted in 43% of patients ( $n = 316$ ) and 33% of patients ( $n = 237$ ), respectively. Overall survival for neonates was 40% as compared with 57% in pediatric patients ( $p < 0.001$ ). Annual survival rates for neonatal and pediatric patients were unchanged ( $p_{\text{trend}} = 0.136$  and  $p_{\text{trend}} = 0.133$ , respectively). Bleeding events were associated with reduced survival for neonates and pediatric cardiac patients by 33% ( $RR_{\text{adj}}$  0.67; 95% CI, 0.51–0.88) and 32% ( $RR_{\text{adj}}$  0.68; 95% CI, 0.55–0.83), respectively. A similar decrease in survival likelihood associated with thrombotic complications was noted for both neonatal patients ( $RR_{\text{adj}}$  0.56; 95% CI, 0.38–0.82) and pediatric patients ( $RR_{\text{adj}}$  0.63; 95% CI, 0.49–0.82).

The bleeding and thrombotic-related complications in patients who underwent ECLS for cardiac failure are presented in **Figure 2**. Increasing frequency of bleeding and thrombotic-related complications were also associated with decreased survival ( $p_{\text{trend (all)}} < 0.01$ ) (**Table 4**).

**Patients Requiring ECLS for Cardiopulmonary Resuscitation**

ECLS was initiated for ECPR in 15% of the non-CDH cohort ( $n = 262$ ), of which 42% were neonates (median age among neonates, 7 d [IQR, 4–12]). Survival among ECPR patients to discharge was 45% and was unchanged across the study years ( $p_{\text{trend}} = 0.282$ ).

Bleeding and thrombotic complications occurred in 38% of patients with ECPR ( $n = 99$ ) and 29% of patients with ECPR ( $n = 77$ ), respectively. Bleeding rates were

similar between neonates and pediatric patients (37% vs 39%;  $p = 0.759$ ), as was the prevalence of thrombosis (30% vs 29%;  $p = 0.790$ ). In neonates, bleeding complications were associated with reduced survival (RR<sub>adj</sub> 0.45; 95% CI, 0.23–0.86) but

thrombosis was not ( $p = 0.124$ ). In pediatric patients, bleeding complications were not associated with survival ( $p = 0.187$ ). The presence of thrombotic complications, however, was associated with reduced survival (RR<sub>adj</sub> 0.59; 95% CI, 0.37–0.95)

**TABLE 3. Frequency<sup>a</sup> of Complications During Extracorporeal Life Support for Respiratory Support and Relative Risk of Survival (Excludes Cases of Congenital Diaphragmatic Hernia)**

| Variable  | Bleeding |          |            |                          |           | Thrombosis |          |            |                          |           |
|-----------|----------|----------|------------|--------------------------|-----------|------------|----------|------------|--------------------------|-----------|
|           | n        | % (n)    | % Survival | Survival RR <sup>b</sup> | 95% CI    | n          | % (n)    | % Survival | Survival RR <sup>b</sup> | 95% CI    |
| Neonatal  | 0        | 75 (389) | 84         | 1.00                     | –         | 0          | 73 (379) | 82         | 1.00                     | –         |
|           | 1        | 22 (115) | 57         | 0.72                     | 0.61–0.85 | 1          | 16 (85)  | 62         | 0.80                     | 0.67–0.95 |
|           | 2+       | 3 (16)   | 31         | 0.36                     | 0.16–0.84 | 2          | 6 (33)   | 67         | 0.83                     | 0.63–1.08 |
|           |          |          |            | $p < 0.001^a$            |           | 3+         | 4 (23)   | 57         | 0.72                     | 0.48–1.08 |
|           |          |          |            |                          |           |            |          |            | $p = 0.009^a$            |           |
| Pediatric | 0        | 50 (133) | 61         | 1.00                     | –         | 0          | 63 (166) | 52         | 1.00                     | –         |
|           | 1        | 33 (87)  | 45         | 0.75                     | 0.57–0.98 | 1          | 22 (58)  | 50         | 0.95                     | 0.70–1.29 |
|           | 2+       | 17 (44)  | 27         | 0.47                     | 0.27–0.81 | 2          | 10 (26)  | 50         | 1.08                     | 0.73–1.61 |
|           |          |          |            | $p = 0.001^a$            |           | 3+         | 5 (14)   | 21         | 0.47                     | 0.17–1.29 |
|           |          |          |            |                          |           |            |          |            | $p = 0.274^a$            |           |

RR = relative risk.

<sup>a</sup>A linear test for trend was performed.

<sup>b</sup>Adjusted for duration of extracorporeal life support (hours) and mode of administration (venoarterial and venovenous).

Dashes indicate that 0 is the reference value.

**TABLE 4. Frequency<sup>a</sup> of Complications During Extracorporeal Life Support for Cardiac Support and Relative Risk of Survival<sup>a</sup> (Excludes Cases of Congenital Diaphragmatic Hernia)**

| Variable  | Bleeding |          |            |                          |           | Thrombosis |          |            |                          |           |
|-----------|----------|----------|------------|--------------------------|-----------|------------|----------|------------|--------------------------|-----------|
|           | n        | % (n)    | % Survival | Survival RR <sup>b</sup> | 95% CI    | n          | % (n)    | % Survival | Survival RR <sup>b</sup> | 95% CI    |
| Neonatal  | 0        | 57 (211) | 49         | 1.00                     | –         | 0          | 68 (251) | 49         | 1.00                     | –         |
|           | 1        | 28 (103) | 35         | 0.80                     | 0.59–1.07 | 1          | 20 (75)  | 21         | 0.51                     | 0.32–0.81 |
|           | 2+       | 16 (58)  | 19         | 0.45                     | 0.26–0.77 | 2          | 8 (29)   | 31         | 0.78                     | 0.45–1.35 |
|           |          |          |            | $p < 0.001^a$            |           | 3+         | 5 (17)   | 12         | 0.36                     | 0.09–1.35 |
|           |          |          |            |                          |           |            |          |            | $p = 0.014^a$            |           |
| Pediatric | 0        | 56 (200) | 69         | 1.00                     | –         | 0          | 67 (239) | 67         | 1.00                     | –         |
|           | 1        | 31 (109) | 42         | 0.66                     | 0.52–0.83 | 1          | 20 (70)  | 41         | 0.67                     | 0.50–0.89 |
|           | 2+       | 13 (46)  | 43         | 0.73                     | 0.52–1.02 | 2          | 10 (35)  | 31         | 0.57                     | 0.34–0.93 |
|           |          |          |            | $p = 0.003^a$            |           | 3+         | 3 (11)   | 27         | 0.58                     | 0.23–1.47 |
|           |          |          |            |                          |           |            |          |            | $p = 0.002^a$            |           |

RR = relative risk.

<sup>a</sup>A linear test for trend was performed.

<sup>b</sup>Adjusted for the duration of extracorporeal life support (hours).

Dashes indicate that 0 is the reference value.

**TABLE 5. Frequency<sup>a</sup> of Complications During Extracorporeal Life Support for Congenital Diaphragmatic Hernia and Relative Risk of Survival**

| Variable | Bleeding |                |            |                          |           | Thrombosis |                |            |                          |           |
|----------|----------|----------------|------------|--------------------------|-----------|------------|----------------|------------|--------------------------|-----------|
|          | <i>n</i> | % ( <i>n</i> ) | % Survival | Survival RR <sup>a</sup> | 95% CI    | <i>n</i>   | % ( <i>n</i> ) | % Survival | Survival RR <sup>a</sup> | 95% CI    |
| Neonatal |          |                |            |                          |           |            |                |            |                          |           |
|          | 0        | 55 (145)       | 50         | 1.00                     | —         | 0          | 40 (104)       | 48         | 1.00                     | —         |
|          | 1        | 34 (89)        | 33         | 0.65                     | 0.46–0.91 | 1          | 29 (75)        | 37         | 0.90                     | 0.62–1.31 |
|          | 2        | 11 (29)        | 24         | 0.53                     | 0.27–1.04 | 2          | 18 (48)        | 38         | 0.95                     | 0.61–1.48 |
|          |          |                |            | <i>p</i> = 0.006         |           | 3          | 14 (36)        | 36         | 0.92                     | 0.55–1.52 |
|          |          |                |            |                          |           |            |                |            | <i>p</i> = 0.740         |           |

RR = relative risk.

<sup>a</sup>A linear test for trend was performed.

<sup>b</sup>Adjusted for the duration of extracorporeal life support (hours).

Dashes indicate that 0 is the reference value.

In the ECPR subgroup, the most common source of bleeding was at surgical sites (16%; *n* = 41/262) while thrombotic complications from hemolysis (12%; *n* = 32/262) and clots in the circuit (12%; *n* = 32/262) predominated.

### Patients Requiring ECLS for CDH

Overall survival for patients with CDH was 41% (*n* = 109/263). No increase in survival was noted over the study time period ( $p_{\text{trend}} = 0.876$ ). Bleeding and thrombotic complications in the CDH group were found in 45% (*n* = 118) and 60% (*n* = 159), respectively. Bleeding complications were associated with reduced survival (RR, 0.62; 95% CI, 0.46–0.86) although thrombotic complications were not (RR, 0.92; 95% CI, 0.67–1.26). Increasing frequency of bleeding complications were also associated with reduced survival likelihood ( $p_{\text{trend}} = 0.006$ ) (Table 5).

## DISCUSSION

In this retrospective analysis of ELSO registry data from clinical sites in CPCCRN, we identified a trend toward increased survival between 2005 and 2011. The majority of improvement is in patients receiving ECLS for respiratory support, as those with ECPR, CDH, and cardiac support had fairly static survival rates over the study period. Such an improvement is encouraging, given that patients receiving ECLS for respiratory failure in the current era are reported to have more comorbidities adversely affecting survival (19).

The reason for poor survivability of neonatal CDH patients receiving ECLS remains elusive. Reports of improved survival due to scoring systems for severity of CDH and treatment or surgical regimens have been limited to single-center studies (20–23). Fatal bleeding events are high among this patient population, and the occurrence of thrombotic events may reflect anticoagulation efforts (24). Our analysis of patients treated within CPCCRN sites found no association between thrombotic events and survival. The absence of an association raises the question about the presence of subclinical thrombus similar to those identified in postmortem examinations of adult populations (25, 26).

Data from this report are subject to limitations similar to those noted in previous reports based on ELSO registry data. Data available for analysis did not allow correlation between timing of bleeding and/or thrombotic events and other factors, such as anticoagulation status, organ failure severity, or specific data on administration of blood products. Similarly, although venoarterial support during ECLS for respiratory support was associated with decreased survival, this may be related to pre-ECLS severity factors or other details rather than the mode itself (27, 28), but specific data points to establish this association are not available within the registry. Outcome measures were limited to survival. Nonetheless, this focused evaluation from academic sites with large ECMO populations and long experience is useful to inform the field of factors associated with outcome in the current era. Our findings highlight a lack of success in development of anticoagulation regimens and ECMO practices and processes to limit or eliminate the occurrence of bleeding and thrombosis.

The variability in ECMO practice between centers remains an ongoing limitation to research on ECLS. The ability to develop studies aimed at a specific anticoagulation regimen or intervention is confounded by nonstandardized ECMO equipment and management algorithms. Perhaps, the time has come to standardize ECMO practice and procedures to aid scientific research and advance the field. This novel approach in ECMO has not been implemented in the past and represents a paradigm shift in ECMO practice, as most centers have developed their own unique practices (29).

To achieve the goal of eliminating bleeding and thrombosis-related death during ECMO, investigations must employ rigorous, prospective observational designs to systematically gather data at a more granular level than is currently available. ELSO is currently revising the registry data fields to strengthen variable definitions (e.g., complications) and to add fields which would allow more exact severity-of-illness scoring as well as identify timing of complications during the ECMO course. This analysis was conducted in preparation for a multicenter trial of bleeding and thrombosis during ECMO among CPCCRN

sites. By capitalizing on the CPCCRN infrastructure, the author and collaborators are in pursuit of a framework to standardize ECMO practice—from circuitry to anticoagulation algorithms to patient management—in order to design and implement scientifically rigorous studies. Successful implementation of such a process within ECLS will open the door for similar efforts throughout critical care medicine (30, 31).

## ACKNOWLEDGMENTS

This project was a collaborative effort between the Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network (CPCCRN) and the Extracorporeal Life Support Organization. We thank all the extracorporeal membrane oxygenation coordinators and directors at CPCCRN sites for their help in data collection and their tireless support of these complex patients.

## REFERENCES

- Bartlett RH, Gattinoni L: Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. *Minerva Anesthesiol* 2010; 76:534–540
- Shuhaiber J, Thiagarajan RR, Laussen PC, et al: Survival of children requiring repeat extracorporeal membrane oxygenation after congenital heart surgery. *Ann Thorac Surg* 2011; 91:1949–1955
- Undar A, McKenzie ED, McGarry MC, et al: Outcomes of congenital heart surgery patients after extracorporeal life support at Texas Children's Hospital. *Artif Organs* 2004; 28:963–966
- Paden ML, Conrad SA, Rycus PT, et al: Extracorporeal Life Support Organization registry report 2012. *ASAIO J* 2013; 59:202–210
- Delmo Walter EM, Alexi-Meskishvili V, Huebler M, et al: Rescue extracorporeal membrane oxygenation in children with refractory cardiac arrest. *Interact Cardiovasc Thorac Surg* 2011; 12:929–934
- Almond CS, Buchholz H, Massicotte P, et al: Berlin heart excor pediatric ventricular assist device investigational device exemption study: Study design and rationale. *Am Heart J* 2011; 162:425–435
- Brogan TV, Thiagarajan RR, Rycus PT, et al: Extracorporeal membrane oxygenation in adults with severe respiratory failure: A multi-center database. *Intensive Care Med* 2009; 35:2105–2114
- Zimmermann M, Bein T, Arlt M, et al: Pumpless extracorporeal interventional lung assist in patients with acute respiratory distress syndrome: A prospective pilot study. *Crit Care* 2009; 13:R10
- Rajagopal SK, Almond CS, Laussen PC, et al: Extracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: A review of the Extracorporeal Life Support Organization registry. *Crit Care Med* 2010; 38:382–387
- Dalton HJ: Extracorporeal membrane oxygenation in the 21st century: A decade of change. *Pediatr Crit Care Med* 2011; 12:692–693
- Bartlett RH, Gazzaniga AB, Huxtable RF, et al: Extracorporeal circulation (ECMO) in neonatal respiratory failure. *J Thorac Cardiovasc Surg* 1977; 74:826–833
- Elg M, Carlsson S, Gustafsson D: Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. *Thromb Res* 2001; 101:145–157
- Chai PJ, Jacobs JP, Dalton HJ, et al: Extracorporeal cardiopulmonary resuscitation for post-operative cardiac arrest: Indications, techniques, controversies, and early results—what is known (and unknown). *Cardiol Young* 2011; 21(Suppl 2):109–117
- Gow KW, Lao OB, Leong T, et al: Extracorporeal life support for adults with malignancy and respiratory or cardiac failure: The Extracorporeal Life Support experience. *Am J Surg* 2010; 199:669–675
- Sniecinski RM, Karkouti K, Levy JH: Managing clotting: A North American perspective. *Curr Opin Anaesthesiol* 2012; 25:74–79
- Oliver WC: Anticoagulation and coagulation management for ECMO. *Semin Cardiothorac Vasc Anesth* 2009; 13:154–175
- Smith A, Hardison D, Bridges B, et al: Red blood cell transfusion volume and mortality among patients receiving extracorporeal membrane oxygenation. *Perfusion* 2013; 28:54–60
- Maclure M, Greenland S: Tests for trend and dose response: Misinterpretations and alternatives. *Am J Epidemiol* 1992; 135:96–104
- Zabrocki LA, Brogan TV, Statler KD, et al: Extracorporeal membrane oxygenation for pediatric respiratory failure: Survival and predictors of mortality. *Crit Care Med* 2011; 39:364–370
- Hirschl RB: Innovative therapies in the management of newborns with congenital diaphragmatic hernia. *Semin Pediatr Surg* 1996; 5:256–265
- Madderom MJ, Toussaint L, van der Cammen-van Zijp MH, et al: Congenital diaphragmatic hernia with(out) ECMO: Impaired development at 8 years. *Arch Dis Child Fetal Neonatal Ed* 2013; 98:F316–F322
- Keijzer R, Wilschut DE, Houmes RJ, et al: Congenital diaphragmatic hernia: To repair on or off extracorporeal membrane oxygenation? *J Pediatr Surg* 2012; 47:631–636
- Hoffman SB, Massaro AN, Gingalewski C, et al: Survival in congenital diaphragmatic hernia: Use of predictive equations in the ECMO population. *Neonatology* 2011; 99:258–265
- Downard CD, Betit P, Chang RW, et al: Impact of AMICAR on hemorrhagic complications of ECMO: A ten-year review. *J Pediatr Surg* 2003; 38:1212–1216
- Rastan AJ, Lachmann N, Walther T, et al: Autopsy findings in patients on postcardiotomy extracorporeal membrane oxygenation (ECMO). *Int J Artif Organs* 2006; 29:1121–1131
- Rastan AJ, Gummert JF, Lachmann N, et al: Significant value of autopsy for quality management in cardiac surgery. *J Thorac Cardiovasc Surg* 2005; 129:1292–1300
- Mehta NM, Turner D, Walsh B, et al: Factors associated with survival in pediatric extracorporeal membrane oxygenation—a single-center experience. *J Pediatr Surg* 2010; 45:1995–2003
- Barrett CS, Bratton SL, Salvin JW, et al: Neurological injury after extracorporeal membrane oxygenation use to aid pediatric cardiopulmonary resuscitation. *Pediatr Crit Care Med* 2009; 10:445–451
- Bemba MM, Annich G, Rycus P, et al: Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: An international survey. *Pediatr Crit Care Med* 2013; 14:e77–e84
- Lequier L, Horton SB, McMullan DM, et al: Extracorporeal membrane oxygenation circuitry. *Pediatr Crit Care Med* 2013; 14:S7–12
- Meyer AD, Wiles AA, Rivera O, et al: Hemolytic and thrombocytopenic characteristics of extracorporeal membrane oxygenation systems at simulated flow rate for neonates. *Pediatr Crit Care Med* 2012; 13:e255–e261